News

Crizotinib Shows Strong Activity Against ALK-Driven Pediatric Cancers


 

FROM THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Overall, the drug was "exceedingly well tolerated," Dr. Mosse said. "Most of the toxicities were extremely low-grade and did not affect overall quality of life. At the highest dose level that we tested, we saw irritation of the liver enzymes that were reversible."

The study was sponsored by the Children’s Oncology Group with collaboration from the National Cancer Institute. Dr. Mosse reported receiving research funding from Pfizer, which makes Xalkori.

Pages

Recommended Reading

JIA Cancer Rates Not Linked to Medication
MDedge Hematology and Oncology
FDA Approves First Quadrivalent Seasonal Flu Vaccine
MDedge Hematology and Oncology
Surgeon General: Decline in Tobacco Use Stalls
MDedge Hematology and Oncology
Infants Left Out of Survival Gains in Childhood Leukemia
MDedge Hematology and Oncology
NCCN Cancer Guidelines Focus on Adolescent, Young Adult Needs
MDedge Hematology and Oncology
NCCN: Stratify Acute Lymphoblastic Leukemia Patients by Age
MDedge Hematology and Oncology
In the Pipeline: Immunotherapy Slows Childhood Gliomas
MDedge Hematology and Oncology
Consider Chemotherapy after Induction Failure for Childhood Leukemia
MDedge Hematology and Oncology
Cixutumumab With Temsirolimus Slows Ewing's Sarcoma
MDedge Hematology and Oncology
Propranolol Considered Standard of Care for Infantile Hemangiomas
MDedge Hematology and Oncology